[go: up one dir, main page]

CL2019001623A1 - Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. - Google Patents

Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.

Info

Publication number
CL2019001623A1
CL2019001623A1 CL2019001623A CL2019001623A CL2019001623A1 CL 2019001623 A1 CL2019001623 A1 CL 2019001623A1 CL 2019001623 A CL2019001623 A CL 2019001623A CL 2019001623 A CL2019001623 A CL 2019001623A CL 2019001623 A1 CL2019001623 A1 CL 2019001623A1
Authority
CL
Chile
Prior art keywords
prevent
relieve
carbamate compound
tremor syndrome
treat
Prior art date
Application number
CL2019001623A
Other languages
English (en)
Inventor
Jin Uk Yoo
Hye Sung Lee
Han Ju Yi
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2019001623A1 publication Critical patent/CL2019001623A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA A UN USO DE UNA COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN COMPUESTO DE CARBAMATO DE LA FÓRMULA QUÍMICA 1 Y SE ADMINISTRA PARA PREVENIR, ALIVIAR O TRATAR TEMBLORES O EL SÍNDROME DE TEMBLOR.
CL2019001623A 2016-12-14 2019-06-12 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. CL2019001623A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14

Publications (1)

Publication Number Publication Date
CL2019001623A1 true CL2019001623A1 (es) 2019-08-23

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001623A CL2019001623A1 (es) 2016-12-14 2019-06-12 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.

Country Status (12)

Country Link
US (1) US11033531B2 (es)
EP (1) EP3556364A4 (es)
JP (1) JP7086076B2 (es)
KR (1) KR102635941B1 (es)
CN (1) CN110267657B (es)
AU (1) AU2017374459B2 (es)
CA (1) CA3046300A1 (es)
CL (1) CL2019001623A1 (es)
IL (1) IL267191B2 (es)
MX (1) MX391363B (es)
WO (1) WO2018111009A1 (es)
ZA (1) ZA201903749B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
AU2019344261B2 (en) * 2018-09-21 2025-03-27 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411917B1 (en) * 2001-02-27 2007-08-08 Ortho-McNeil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
EP1732564A1 (en) * 2004-03-29 2006-12-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
DK2114393T3 (da) * 2007-03-05 2013-07-08 Indus Biotech Private Ltd Farmaceutiske sammensætninger omfattende trigonellin og 4-hydroxyisoleucin og fremgangsmåde hertil
CA2765566C (en) 2009-06-22 2016-04-12 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
WO2014142477A1 (en) 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes
KR102489052B1 (ko) 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
RU2019121914A3 (es) 2021-04-21
EP3556364A1 (en) 2019-10-23
JP2020502137A (ja) 2020-01-23
RU2019121914A (ru) 2021-01-15
MX2019006941A (es) 2019-09-06
KR20190087573A (ko) 2019-07-24
US20190336481A1 (en) 2019-11-07
CA3046300A1 (en) 2018-06-21
KR102635941B1 (ko) 2024-02-13
BR112019012000A2 (pt) 2019-10-29
IL267191B2 (en) 2023-05-01
MX391363B (es) 2025-03-21
JP7086076B2 (ja) 2022-06-17
IL267191A (es) 2019-07-31
AU2017374459A1 (en) 2019-07-04
WO2018111009A1 (ko) 2018-06-21
CN110267657A (zh) 2019-09-20
US11033531B2 (en) 2021-06-15
IL267191B1 (en) 2023-01-01
EP3556364A4 (en) 2020-06-17
CN110267657B (zh) 2022-12-13
AU2017374459B2 (en) 2023-04-27
ZA201903749B (en) 2022-01-26

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
UY37789A (es) Nuevos derivados de azaquinolina
UY37831A (es) Nuevos derivados de quinolina
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX378509B (es) Compuesto de pirimidina y su uso farmaceutico.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2019012522A (es) Compuestos y metodos terapeuticos.
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
PE20161385A1 (es) Formulacion inmunosupresora
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX377172B (es) Formulacion de combinacion de tesofensina y betabloqueante
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CO2022000270A2 (es) Inhibidores de enzimas
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer